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Background: People who inject drugs (PWID) around the world are disproportionately affected 
by the HIV epidemic. National policy responses to the epidemic heavily influence risk factors 
for HIV acquisition among this key group. Prior efforts to monitor national policy responses to 
HIV/AIDS among PWID were limited both in scope and coverage. In this paper we develop 
and validate the HIV-PWID Policy Index (HPPI) to benchmark and monitor national 
commitments to HIV prevention and treatment among PWID. 
Methods: Composite indicator was constructed employing fuzzy multilayer data envelopment 
analysis (FMLDEA). Model inputs based on data from 105 countries included 27 variables 
measured across six conceptual domains, including needle and syringe programs, opioid 
substitution treatment, testing and counseling, information and education, monitoring and 
evaluation, and legal and policy climate. 
Results: According to the HPPI, the top performing countries in commitment to HIV prevention 
and treatment among PWID were Spain (0.988), Switzerland (0.982), Luxembourg (0.970), 
Moldova (0.970), and Kyrgyzstan (0.945), whereas the poorest performing included Nicaragua 
(0.094), Japan, (0.094), Cape Verde (0.097), Syria (0.174), and Benin (0.185). Regionally, 
commitment to HIV services targeting PWID was highest among European countries (0.81) 
and lowest among African countries (0.50), with Oceania (0.76), Asia (0.66), and the Americas 
(0.56) in the mid-range. Subregional differences were even more prominent, with West and 
Central European nations (0.84) and Central American nations (0.22) earning the highest and 
lowest HPPI scores, respectively.  
Conclusions: The HPPI documented substantial national and regional variation in policy 
responses to the HIV epidemic among PWID. Our analysis also revealed that many countries 
have limited HIV/AIDS data collection and monitoring capabilities. Continued enhancement 
and standardization of global HIV/AIDS monitoring efforts are therefore vital to articulated 
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Injection drug use is a major global public health issue. There are an estimated 15.6 
million people worldwide who inject illicit drugs each year, and about one in six of these 
individuals live with HIV (Degenhardt, et al., 2017). People who inject drugs (PWID) are 24 
times more likely to acquire HIV than people in the general population, with new HIV 
infections among PWID continuing to climb in many regions of the world (UNAIDS, 2015a, 
2016).  
National educational, prevention, treatment, and legal responses to the problem of 
injection drug use heavily influence both the macro and micro risk factors for HIV acquisition 
among PWID. Investments in evidence-based prevention and treatment interventions—such as 
opioid substitution, needle exchange, and antiretroviral therapy—can substantially curtail the 
spread of HIV among PWID (Strathdee, et al., 2010). However, only about half the world’s 
countries implement evidence-based harm reduction policies aimed at preventing the spread of 
HIV among PWID (Harm Reduction International, 2016), and many others continue to subject 
this population to punitive criminal justice measures and other counterproductive responses 
(Lunze, et al., 2014; Strathdee, Beletsky, & Kerr, 2015).  
In reaffirming international efforts to end the HIV/AIDS epidemic by 2030, the UN 
General Assembly adopted the Political Declaration on HIV and AIDS (United Nations, 2016). 
UNAIDS has set a goal of achieving 90% access to PWID-tailored HIV prevention services by 
2020, including HIV testing, antiretroviral therapies (ART), needle and syringe exchange 
programs (NSPs), opioid substitution therapy (OST), safe sex programming, education and 
outreach, and related clinical services (UNAIDS, 2015b). Systematic reviews of the global 
epidemiology of HIV/AIDS among PWID and the associated global, regional, and national 
policy responses emphasize the need for comprehensive monitoring and assessment tools to 
achieve these objectives (e.g., Mathers, et al., 2010; Mathers, et al., 2008). Indeed, Beyrer, et 
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al. (2010) articulated a specific need for a national HIV/AIDS accountability matrix to 
document country-level interventions targeting PWID (see also Degenhardt, et al., 2014). 
Toward this end, the current study develops the HIV-PWID Policy Index (HPPI), which is the 
first global policy index measuring national commitments to HIV/AIDS prevention and 
treatment interventions for PWID. During the last decade, many composite indexes (CIs) have 
been developed in the domains of economics, governance, security, environment, 
sustainability, and public health (Botero, Nelson, & Pratt, 2011; Moxham‐Hall & Ritter, 2017; 
Pissourios, 2013). The proliferation of these types of CIs is an indication of their importance 
for performance evaluation, benchmarking, and decision-making. 
Previous HIV/AIDS Policy Monitoring Efforts 
Several prior efforts have been undertaken to monitor national policy responses to 
HIV/AIDS, but they remain limited in scope and coverage with respect to PWID. Desmond 
and colleagues (2008) developed an early model to rank country efforts against HIV/AIDS 
based on three narrowly targeted indicators (prevention of mother-to-child HIV transmission, 
antiretroviral treatment coverage, and the ratio of orphans to non-orphans attending school). 
The AIDS Accountability Country Scorecard (AIDS Accountability International, 2008) 
represents a more comprehensive effort based on monitoring data across eight domains (data 
collection, at-risk populations, treatment, prevention, coordination, civil society, financing, and 
human rights). Individual country scores were not reported, however, limiting the scorecard’s 
utility for informing national strategic responses.  
 Other monitoring efforts have developed composite indexes (CIs) that aggregate 
different policy indicators into a single score. The AIDS Program Effort Index (API) measures 
levels of national HIV programming and support for 54 countries across ten policy domains 
(political support; policy and planning; organizational structure; program resources; 
evaluation, monitoring, and research; legal and regulatory environment; human rights; 
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prevention programs; care and treatment services; and mitigation programs) (Stover, 2001; see 
also USAID, UNAIDS, WHO, & the POLICY Project, 2003). Alfven, et al. (2014) developed 
the HIV Monitoring and Evaluation System Capacity Index (MESCI) based on reports for 78 
countries measuring national HIV commitments, government engagement, partner/civil society 
engagement, and data generation. None of these prior indices, however, focus on the target 
population of PWID that motivates the current study. 
 To our knowledge, the Policy Environment Index for PWID (PEIP) is the only 
monitoring effort that addresses the HIV/AIDS policy environment for injection drug users 
(Platt, et al., 2015). The index is based on six indicators measured across three domains: 
meaningful engagement of stakeholders (evidence of a national organization of drug users), 
coordinated national strategy for HIV prevention and drug use (evidence of explicit inclusion 
of harm reduction in national-level strategy, monitoring/evaluation studies documenting HIV 
among PWID), and evidence-based HIV prevention intervention approaches (presence of OST 
and NSP, presence of OST and NSP in prison settings, evidence of decriminalization of drug 
possession and use). PEIP was constructed for 50 European region countries, with higher 
(lower) index scores suggesting an enabling (constraining) policy environment for HIV 
prevention among PWID. Although representing a step forward in measuring commitments to 
HIV prevention and treatment among PWID, PEIP is based on a small number of indicators 
for European countries. In developing the HIV-PWID Policy Index (HPPI), the current study 
aims to extend prior research by expanding the number of underlying indicators, increasing 
coverage to more world regions, and presenting individual results for each country.  
Methods 
Construction of the HPPI proceeded in several steps. First, we developed a conceptual 
framework to guide the identification of domains and selection of policy indicators for 
constructing the HPPI. Second, we reviewed the quality and availability of country-level 
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indicators, while also addressing missingness and normalization concerns. Third, we employed 
fuzzy multilayer data envelopment analysis (FMLDEA) to aggregate the indicators into a 
composite index, with higher scores reflecting a stronger commitment to HIV risk reduction 
among PWID. Each of these steps is discussed in more detail in the following sections.  
Conceptual Framework 
The HPPI conceptual framework was developed based on a comprehensive review of 
the evidence-based literature on HIV interventions targeting PWID and the first two authors’ 
subject area expertise. Our conceptual framework comprises six policy domains: (1) Needle 
and Syringe Programs, (2) Opioid Substitution Treatment, (3) Testing and Treatment, (4) 
Information and Education, (5) Monitoring and Evaluation, and (6) Legal and Policy Climate. 
To populate the domains with relevant indicators, we examined data sources produced by 
leading international governmental (UNAIDS, UNODC, WHO, EMCDDA) and 
nongovernmental organizations (Harm Reduction International). We also reviewed relevant 
peer-reviewed publications and other reports for additional data. Table 1 presents the 
conceptual framework and associated indicators, with more detailed definitions and source 
information presented in Appendix I. 
Domain 1, Needle and Syringe Programs (NSPs), captures traditional and prison-based 
syringe distribution programming with demonstrated effectiveness in reducing HIV 
transmission and other injection risk behaviors among PWID (Fernandes, et al., 2017; Gibson, 
Flynn, & Perales, 2001; Wodak & Cooney, 2006). We also include supervised injection 
facilities (SIFs) in this domain since these sites offer a host of services that promote safer 
injection conditions and practices that reduce rates of HIV infection among PWID (Andresen 
& Jozaghi, 2012; Kennedy, Karamouzian, & Kerr, 2017; Pardo, Kilmer, & Caulkins, 2018; 
Pinkerton, 2011; Potier, Laprévote, Dubois-Arber, Cottencin, & Rolland, 2014). Domain 1 also 
captures the domestic policy environment pertaining to the promotion of safe injection 
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behaviors, which can influence the development and sustainability of NSP interventions 
(Hayle, 2018). 
Domain 2, Opioid Substitution Treatment (OST), measures opioid agonist treatments 
that have been shown to be effective in reducing HIV infections and risky behaviors among 
injection drug users (Ahamad, et al., 2015; Karki, Shrestha, Huedo-Medina, & Copenhaver, 
2016; MacArthur, et al., 2012; Marks, et al., 2019), including in prison-based settings (Larney, 
2010). The national policy stance toward OST among PWID is also measured in Domain 2, as 
political will and national commitments influence the ability to scale up OST interventions 
(Reid, Sharma, & Higgs, 2014).  
Testing and Treatment interventions are captured in Domain 3. Despite often poor 
treatment adherence among injection drug users (Lert & Kazatchkine, 2007), detect-and-treat 
interventions can significantly reduce HIV transmission risk among PWID (Des Jarlais, et al., 
2016; Montaner, et al., 2010). Consequently, national preventive strategies regarding HIV 
testing and counseling among PWID, as well as the accessibility of antiretroviral treatment 
(ART), are measured in this domain.  
Domain 4, Information and Education, captures national policy efforts designed to 
improve health and reduce risky behaviors among PWID. Although the evidence regarding the 
health-promoting effects of mass media information, education, and communication efforts 
targeting PWID is not strong (Aggleton, Jenkins, & Malcolm, 2005), social media and mobile 
health interventions are promising and require further investigation (Cao, et al., 2017; Genz, et 
al., 2015). Domain 5, Monitoring and Evaluation, captures national HIV monitoring and 
evaluation efforts, which are integral to understanding and shaping HIV interventions among 
PWID and other vulnerable populations (Alfven, et al., 2017; Gall, et al., 2017; Weir, et al., 
2018). Finally, Domain 6, Legal and Policy Climate, captures aspects of the policy environment 
concerning both HIV and PWID, as de-stigmatization and decriminalization of these statuses 
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can promote and reinforce effective prevention and treatment efforts (Baker, et al., 2019; 
DeBeck, et al., 2017; Strathdee, et al., 2015; Strathdee, et al., 2010).  
 [INSERT TABLE 1 ABOUT HERE] 
Assessment and Treatment of Indicators 
Across all indicators, we initially collected data on 181 countries. We dropped 76 
countries from the analysis due to missing data on five or more policy indicators, resulting in 
a final analytic sample of n = 105 countries. Among included countries, the ratio of missing to 
total data was just 1.4%.1 We imputed data in these instances by taking either the modal value 
for binary indicators or using the average ratio method for continuous and ordinal data 
(Tamaddon, Jahanshahloo, Lotfi, Mozaffari, & Gholami, 2009).  
Next, we normalized the data to place all measures on a similar scale, which is a 
necessary step prior to index construction. We adopted the distance-to-reference approach, 
using the maximum reported indicator value as the reference for continuous and ordinal data; 
binary data were not normalized (see Organisation for Economic Co-operation and 
Development, 2008).  
Constructing the HIV-PWID Policy Index  
Recent progress in the development of CIs includes both objective methods and 
subjective methods (Greco, Ishizaka, Tasiou, & Torrisi, 2019). A common feature of many of 
these methods is the assumption of uniform indicator weights for the DMUs under study, which 
ignores the relative ‘importance’ of each indicator and makes it difficult to ascertain unit-
specific predictors of performance. In this respect, data envelopment analysis (DEA) offers 
several advantages over other CI construction methods. First, DEA can be used to combine 
multiple indicators without prior knowledge of their trade-offs, i.e., weights. Second, DEA 
 
1 The percentage of missing data by indicator was 0% except as follows: v1.2 (8.6%), v3.2 (5.7%), v5.2 (4.8%), 
v6.1 (7.6%), v6.3 (1.9%), v6.4 (1.0%), v6.6 (1.0%), v6.7 (1.0%), v6.8 (1.0%), and v6.9 (4.8%). 
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evaluates the relative performance of DMUs to ensure that each unit obtains the best possible 
set of indicator weights (Cherchye, Moesen, Rogge, & Puyenbroeck, 2007). Any other possible 
set of weights would produce a lower (i.e., less favorable) composite index score.  
Applications of DEA for CI construction often focus on policy indicators. Basic DEA 
models assume that the data are both quantitative and nonhierarchical. Neither of these 
assumptions holds for the current study. To combine both quantitative and qualitative data, we 
follow Shen and colleagues (Shen, Hermans, Brijs, & Wets, 2014; Shen, Ruan, et al., 2011) in 
implementing a fuzzy DEA approach that interprets qualitative data as fuzzy numerical values, 
which can be incorporated into the model with varying degrees of certainty, h. When h=1, 
qualitative data are treated as numerical and the results are equivalent to crisp DEA. When h<1, 
a more cautious approach is taken regarding measurement precision, resulting in a wider range 
of index scores for each country. Further, within each h degree, we present three different 
scenario weights for each DMU in producing a set of pessimistic, indifferent, and optimistic 
index scores. To account for the hierachical nature of our conceptual framework, we follow 
Shen and colleagues (Shen, Hermans, Brijs, & Wets, 2013; Shen, Hermans, et al., 2011) 
multilayer DEA model which incorporates different types of the possible weight restrictions 
for each domain. Integrating these two approaches produces a fuzzy multilayer DEA 
(FMLDEA) model. Finally, we employ a cross-efficiency extension to DEA developed by 
Sexton, Silkman, and Hogan (1986) to effectively rank the DMUs (i.e., countries) on 
performance. See Appendix II for technical details of these specifications. All models were 
solved with the optimization modeling software Lingo 13.0 (Lindo Systems, 2017). 
Results 
Country-level results of the FMLDEA-based CI model are presented in Table 2. CI 
scores are presented as the cross efficiency scores for the indifferent scenario for h=0.5, 
reflecting medium performance while incorporating some decision-maker uncertainty about 
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the crispness of the data (see Appendix III for sensitivity analyses). The quartile distribution of 
these index scores is mapped in Figure 1. The discriminatory power of the model could be 
improved by imposing some restrictions on the indicator weights derived from expert opinion, 
but given that the scores derived from the cross-effeciency matrix provide good discrimination 
among the DMUs, we allow the weights to be calculated freely and directly by the model.  
[INSERT TABLE 2 ABOUT HERE] 
[INSERT FIGURE 1 ABOUT HERE] 
The top-performing decile of countries include six from Europe (Spain, Switzerland, 
Luxemborg, Moldava, Norway, and France), three from Asia (Kyrgystan, Armenia, and India), 
and one each from the Americas (Canada) and Oceania (Australia). Conversely, the bottom 
performing decile of countries includes five from Asia (Maldives, Bahrain, Oman, Syria, and 
Japan), four from Africa (Seychelles, Libya, Benin, and Cape Verde), and two from the 
Americas (Honduras and Nicaragua).  
Table 3 presents the mean HPPI scores by region, revealing that commitment to HIV 
services among PWID is highest among European countries, with index scores for each 
European subregion above the global mean index score (0.67). Among European countries, 
only Cyprus (0.65), Croatia, (0.64), Macedonia (0.57), and Turkey (0.46) had index scores 
below the global mean. Oceanic countries also recorded above-average index scores on 
commitment to HIV programming among PWID, an outcome driven by high-performing 
Australia (0.91). Overall, index scores from Asian countries were on par with the global 
average, but this average masks considerable subregional variation. Central Asian countries, 
for instance, are substantially higher performing (0.85) than Near and Middle East countries 
(0.33). Countries in the Americas recorded an average index score lower than the global mean, 
but this average also obscures substantial variation by subregion as indicated by the extremes 
reported for North America (0.82) and Central America (0.22). Lastly, both regionally and 
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subregionally, African countries performed poorest on commitment to HIV programming 
among PWID, with no African subregion attaining a mean index score above the global 
average, despite certain individual African countries performing highly (e.g., top-20 ranked 
Mauritius and Morocco).  
[INSERT TABLE 3 ABOUT HERE] 
Construct Validity of the HIV-PWID Policy Index  
The HPPI is broadly consistent with national and regional commitments to HIV 
prevention and treatment as indicated by a recent systematic review of available literature and 
data (Larney, et al., 2017). To more formally assess the construct validity of the HPPI, we 
compared our results with Platt et al.’s (2015) Policy Environment Index for PWID. As shown 
in Figure 2 for the 44 overlapping countries, there is a moderate sized positive correlation (r = 
0.51) between the two composite indicators.2 Although Platt et al. (2015) used six indicators 
across three domains compared to the 27 indicators across six domains used to construct the 
HPPI, the convergence of the two indices provides supporting evidence that the HPPI is 
measuring national commitments to HIV prevention and treatment among PWID.  
[INSERT FIGURE 2 ABOUT HERE] 
Discussion  
 The global prevalence of HIV and other infectious diseases among PWID has increased 
in recent years, with a growing list of countries documenting evidence of injection drug use 
(Degenhardt, et al., 2017). At the same time, effective interventions for preventing and treating 
HIV among PWID are being increasingly adopted by nations across the globe (Larney, et al., 
2017). Still, reliable and comprehensive information about national implementation and local 
coverage of these interventions remains scarce, especially among vulnerable populations. 
While international agencies such as UNAIDS and WHO have greatly expanded monitoring 
 
2 Note that instead of reporting raw index scores, Platt et al. (2015) grouped scores into five ranked categories. 
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and evaluation capabilities, few efforts have systematically documented country-level progress 
and commitments supporting the international goal of ending the HIV/AIDS epidemic by 2030 
(UNAIDS, 2016).  
Against this backdrop, the current study developed the HIV-PWID Policy Index (HPPI) 
to parsimoniously measure national commitments to HIV prevention and treatment 
interventions targeting PWID. Specifically, we marshalled 27 indicators across six conceptual 
domains and implemented an innovative fuzzy multiple layer data envelopment analysis 
(FMLDEA) model to summarize national efforts for 105 countries. Previous index construction 
efforts in this area used less robust methods, incorporated fewer measures, or focused on a 
smaller subset of countries. The HPPI thus stands as a promising new tool with utility for 
country-level performance evaluation, benchmarking, and decision-making for HIV 
interventions targeting PWID.  
The HPPI documented substantial national and regional variation in policy responses 
to the HIV epidemic among PWID. Top performing countries on the HPPI clustered in several 
world subregions: Central Asia (0.85), West and Central Europe (0.84), Eastern Europe (0.83), 
and North America (0.82). High performance of Western European and North American 
countries might be explained by their sizable and entrenched numbers of PWID that 
necessitated and justified public health oriented and evidenced-based responses to the HIV 
epidemic among this population. High performace of Central and Eastern European countries 
might be attributable to the acuteness of the HIV epidemic among PWID following the collapse 
of the Soviet Union, together with national coordinating mechanisms (excepting Russia) that 
support the implementation of evidenced-based responses recommended by the major 
international public health bodies, such as WHO and UNAIDS.  
In contrast, the poorest performing countries tended to be located in Southern Africa 
(0.48), West and Central Africa (0.38), Near and Middle East (0.33), and Central America 
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(0.22). A partial explanation for poor policy performance in these regions could be that the 
numbers of PWID are relatively low—e.g. 0.12% among people aged 15–64 years in the 
Middle East and North Africa, and 0.28% in the Sub-Saharan Africa compared to 1.30% in the 
Eastern Europe (Degenhardt et al., 2017). Accordingly, the HIV epidemic among PWID in 
countries of these regions may not be percevied as salient enough to warrant adopting domestic 
policies that are in accordance with international public health guidelines. 
As a monitoring tool, the HPPI is only as reliable as the underlying data that goes into 
its construction. Measuring stigmatized behaviors and populations, including the associated 
policy responses that may not be officially sanctioned (e.g., needle exchange, safe injection 
sites), is challenging. Doing this well across dozens of countries is even more daunting, 
especially when high-level policies do not reflect what is actually happening on the ground or 
political considerations impede reporting to international agencies. As a case in point, 
Kyrgyzstan is ranked fifth on the HPPI because the government promotes evidence-based 
interventions targeting HIV prevention and treatment among PWID, including official support 
for NSPs. However, recent research has documented significant individual-level barriers to 
accessing NSP services by PWID in Kyrgyzstan (Deryabina & El-Sadr, 2017), which are 
unlikely to be captured by national policy indicators. Another limitation of the HPPI is that the 
applied model cannot be used to decompose the rank of countries by domain. Nevertheless, 
country-level indicators are reported in a supplemental data file to enable detailed inspection 
and assessment of each nation’s policy stance.  
Our findings point to the urgent need for both country-specific and regional efforts to 
improve HIV prevention programming, treatment service delivery, and legal/policy 
environments for PWID. However, as demonstrated in the global heat map of the HPPI in 
Figure 1, countries from certain world regions, including much of sub-Saharan Africa and 
South America, have limited HIV/AIDS data and monitoring capabilities, highlighting regional 
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opportunities for improving targeted data collection efforts. Continued enhancement and 
standardization of global HIV/AIDS monitoring efforts efforts are therefore vital to national 
and international benchmarking and performance assessment goals.  
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Table 1. Conceptual Framework for HIV-PWID Policy Index (HPPI) and Selected Indicators 
Domains and Indicators Measurement Range 
1. Needle and Syringe Programs (NSPs)  
1.1 NSPs Operational 0-1 
1.2 Syringes Distributed per PWID 0-565 
1.3 NSPs Operational in Prison 0-1 
1.4 Supervised Injection Facilities Operational 0-1 
1.5 National Policy Promotes Use of Clean Needles in HIV Awareness 0-1 
1.6 National Policy Promotes Needle Exchange among PWID 0-1 
2. Opioid Substitution Treatment (OST)  
2.1 OST Programs Operational 0-1 
2.2 OST Operational in Prison 0-1 
2.3 National Policy Promotes OST among PWID 0-1 
3. Testing and Treatment (TT)  
3.1 National Policy Promotes Testing and Counseling among PWID 0-1 
3.2 Antiretroviral Treatment Accessibility 2.5-5 
4. Information and Education (IE)  
4.1. National Policy Promotes Use of Condoms among PWID  0-1 
4.2. National Policy Promotes Reproductive Health among PWID 0-1 
4.3. National Policy Promotes Stigma Reduction among PWID 0-1 
4.4. National Policy Promotes Risk Reduction among PWID  0-1 
4.5. National Policy Promotes Vulnerability Reduction among PWID 0-1 
5. Monitoring and Evaluation (ME)  
5.1 National HIV Monitoring and Evaluation Plan 1-3 
5.2 Quality of HIV-Related Monitoring and Evaluation 0-10 
6. Legal and Policy Climate (LPC)  
6.1 Support for Harm Reduction in National Policy Documents 0-1 
6.2 Country Has National HIV Coordinating Body 0-1 
6.3 Vulnerable Populations Involved in HIV Policy Development 0-1 
6.4 Country Has No HIV-Related Travel Restrictions 0-1 
6.5 National Strategy Addresses PWID 0-1 
6.6 PWID Identified as Target Group for HIV Programming 0-1 
6.7 Nondiscrimination Laws Protect PWID 0-1 
6.8 Laws Support Effective HIV Response among PWID 0-1 
6.9 Extent of Harm Reduction Resources for PWID 1-4 







Table 2. HIV-PWID Policy Index (HPPI) Results 
Country Region Subregion 
Index Scores for 
Indifferent and h=0.5 
Score Ranking 
Spain Europe West and Central Europe 0.9883 1 
Switzerland Europe West and Central Europe 0.9822 2 
Luxembourg Europe West and Central Europe 0.9703 3 
Moldova Europe Eastern Europe 0.9701 4 
Kyrgyzstan Asia Central Asia 0.9452 5 
Armenia Asia Central Asia 0.9253 6 
Norway Europe West and Central Europe 0.9213 7 
France Europe West and Central Europe 0.9209 8 
Canada Americas North America 0.9176 9 
Australia Oceania Oceania 0.9056 10 
India Asia South Asia 0.8963 11 
Montenegro Europe South Eastern Europe 0.8846 12 
Portugal Europe West and Central Europe 0.8833 13 
Mauritius Africa East Africa 0.8814 14 
Sweden Europe West and Central Europe 0.8812 15 
Estonia Europe West and Central Europe 0.8804 16 
Morocco Africa North Africa 0.8796 17 
Iran Asia Southwest Asia 0.8794 18 
Vietnam Asia East and Southeast Asia 0.8788 19 
Poland Europe West and Central Europe 0.8766 20 
Indonesia Asia East and Southeast Asia 0.8766 21 
Germany Europe West and Central Europe 0.8764 22 
Macau Asia East and Southeast Asia 0.8755 23 
Serbia Europe South Eastern Europe 0.8738 24 
Tajikistan Asia Central Asia 0.8726 25 
Slovenia Europe West and Central Europe 0.8718 26 
Lithuania Europe West and Central Europe 0.8705 27 
Latvia Europe West and Central Europe 0.8697 28 
Bulgaria Europe South Eastern Europe 0.8697 29 
Georgia Asia Central Asia 0.8678 30 
Romania Europe South Eastern Europe 0.8344 31 
Italy Europe West and Central Europe 0.8321 32 
Netherlands Europe West and Central Europe 0.8292 33 
Denmark Europe West and Central Europe 0.8280 34 
Cambodia Asia East and Southeast Asia 0.8268 35 
Tunisia Africa North Africa 0.8241 36 
China Asia East and Southeast Asia 0.8162 37 
Myanmar Asia East and Southeast Asia 0.8137 38 
Bangladesh Asia South Asia 0.8064 39 
Slovakia Europe West and Central Europe 0.8036 40 
Hungary Europe West and Central Europe 0.8033 41 
Kazakhstan Asia Central Asia 0.7989 42 
Tanzania Africa East Africa 0.7964 43 
Nepal Asia South Asia 0.7958 44 
Azerbaijan Asia Central Asia 0.7955 45 
Afghanistan Asia Southwest Asia 0.7951 46 
Ukraine Europe Eastern Europe 0.7940 47 
Belarus Europe Eastern Europe 0.7921 48 
Senegal Africa West and Central Africa 0.7906 49 
Mexico Americas North America 0.7899 50 
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Kenya Africa East Africa 0.7896 51 
Thailand Asia East and Southeast Asia 0.7872 52 
United Kingdom Europe West and Central Europe 0.7841 53 
Belgium Europe West and Central Europe 0.7836 54 
Greece Europe West and Central Europe 0.7828 55 
Czech Republic Europe West and Central Europe 0.7750 56 
United States Americas North America 0.7668 57 
Uzbekistan Asia Central Asia 0.7554 58 
Russia Europe Eastern Europe 0.7449 59 
Egypt Africa North Africa 0.7445 60 
Philippines Asia East and Southeast Asia 0.7276 61 
Dominican 
Republic 
Americas Caribbean 0.7190 62 
Malta Europe West and Central Europe 0.7097 63 
Finland Europe West and Central Europe 0.6994 64 
Bosnia and 
Herzegovina 
Europe South Eastern Europe 0.6917 65 
Lebanon Asia Near and Middle East 0.6890 66 
Albania Europe South Eastern Europe 0.6806 67 
South Africa Africa Southern Africa 0.6799 68 
Pakistan Asia Southwest Asia 0.6795 69 
Malaysia Asia East and Southeast Asia 0.6785 70 
Brazil Americas South America 0.6759 71 
Paraguay Americas South America 0.6706 72 
Cyprus Europe West and Central Europe 0.6519 73 
Croatia Europe South Eastern Europe 0.6393 74 
DR Congo Africa West and Central Africa 0.6384 75 
Argentina Americas South America 0.6362 76 
New Zealand Oceania Oceania 0.6147 77 
Macedonia Europe South Eastern Europe 0.5700 78 
Colombia Americas South America 0.4941 79 
Turkey Europe South Eastern Europe 0.4567 80 
Uruguay Americas South America 0.4541 81 
Jordan Asia Near and Middle East 0.4465 82 
Algeria Africa North Africa 0.3993 83 
Madagascar Africa East Africa 0.3910 84 
Nigeria Africa West and Central Africa 0.3707 85 
Ghana Africa West and Central Africa 0.3704 86 
Togo Africa West and Central Africa 0.3591 87 
Sri Lanka Asia South Asia 0.3585 88 
Côte d'Ivoire Africa West and Central Africa 0.3293 89 
Saudi Arabia Asia Near and Middle East 0.3159 90 
Kuwait Asia Near and Middle East 0.3104 91 
Liberia Africa West and Central Africa 0.3080 92 
Guatemala Americas Central America 0.2815 93 
Mozambique Africa Southern Africa 0.2808 94 
Honduras Americas Central America 0.2789 95 
Seychelles Africa East Africa 0.2470 96 
Libya Africa North Africa 0.2271 97 
Maldives Asia South Asia 0.2098 98 
Bahrain Asia Near and Middle East 0.1970 99 
Oman Asia Near and Middle East 0.1966 100 
Benin Africa West and Central Africa 0.1846 101 
Syria Asia Near and Middle East 0.1739 102 
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Cape Verde Africa West and Central Africa 0.0972 103 
Japan Asia East and Southeast Asia 0.0942 104 
Nicaragua Americas Central America 0.0935 105 
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Table 3. HIV-PWID Policy Index (HPPI) Scores 
by Region 
Region Mean  Min Max 
Europe 0.81 0.46 0.99 
 Eastern Europe 0.83 0.74 0.97 
 South Eastern Europe 0.72 0.46 0.88 
 West and Central Europe 0.84 0.65 0.99 
Asia 0.66 0.09 0.95 
 Central Asia 0.85 0.76 0.95 
 East and Southeast Asia 0.74 0.09 0.88 
 Near and Middle East 0.33 0.17 0.69 
 South Asia 0.61 0.21 0.90 
 Southwest Asia 0.78 0.68 0.88 
Americas 0.56 0.09 0.92 
 Caribbean 0.72 0.72 0.72 
 Central America 0.22 0.09 0.28 
 North America 0.82 0.77 0.92 
 South America 0.59 0.45 0.68 
Oceania 0.76 0.61 0.91 
Africa 0.50 0.10 0.88 
 East Africa 0.62 0.25 0.88 
 North Africa 0.61 0.23 0.88 
 Southern Africa 0.48 0.28 0.68 
 West and Central Africa 0.38 0.10 0.79 






Figure 1. HPPI Scores Indicating Commitment to HIV Programming among PWID 
  




Figure 2. Comparison of HPPI Results with Platt et al. (2015) for 44 European Countries 
 
